Lineage Cell Therapeutics, Inc. (LCTX) Stock Price, Quote & AI Analysis

Live LCTX stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Lineage Cell Therapeutics, Inc..

TradeVae provides AI-driven analysis and real-time market intelligence for Lineage Cell Therapeutics, Inc. (LCTX), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

LCTX
Lineage Cell Therapeutics, Inc.
real-time
$0.00 +0.00 (+0.00%)
Open
1.700000
High
1.740000
Low
1.655000
Volume
1,079,364
VWAP
-
Market Cap
$366,220,783.83
52W Range
$0.37 - $2.09
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 9, 2026 Q4
After Hours
EPS Estimate: $-0.0493
Revenue Estimate: $2,628,876.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Lineage Cell Therapeutics, Inc.'s fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Lineage Cell Therapeutics, Inc. Overview

Company information

Company Overview

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Company Details
Market Cap
$393.86M
Shares Outstanding
230,328,000
Weighted Shares Outstanding
230,327,537
CEO
Brian M. Culley
Address
2173 SALK AVENUE, CARLSBAD, CA, 92008
Employees
77
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
XASE

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Lineage Cell Therapeutics, Inc. Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...